Biblio
“Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls.”, J Alzheimers Dis, vol. 58, no. 2, pp. 471-478, 2017.
, “Tau Pathology Promotes the Reorganization of the Extracellular Matrix and Inhibits the Formation of Perineuronal Nets by Regulating the Expression and the Distribution of Hyaluronic Acid Synthases.”, J Alzheimers Dis, vol. 57, no. 2, pp. 395-409, 2017.
, “Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1595-1603, 2017.
, “Tau Protein Dysfunction after Brain Ischemia.”, J Alzheimers Dis, vol. 66, no. 2, pp. 429-437, 2018.
, “Tau Proteins Cross the Blood-Brain Barrier.”, J Alzheimers Dis, vol. 55, no. 1, pp. 411-419, 2017.
, “Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers.”, J Alzheimers Dis, vol. 63, no. 1, pp. 13-33, 2018.
, “Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study.”, J Alzheimers Dis, vol. 55, no. 2, pp. 585-595, 2017.
, “Tauopathies: Mechanisms and Therapeutic Strategies.”, J Alzheimers Dis, vol. 61, no. 2, pp. 487-508, 2018.
, “TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1227-1233, 2018.
, “TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study.”, J Alzheimers Dis, vol. 66, no. 4, pp. 1549-1558, 2018.
, “TDP-43 Pathology in the Setting of Intermediate and High Alzheimer's Disease Neuropathologic Changes: A Preliminary Evaluation Across Ethnoracial Groups.”, J Alzheimers Dis, vol. 91, no. 4, pp. 1291-1301, 2023.
, “Telemedicine for Delivery of Care in Frontotemporal Lobar Degeneration During COVID-19 Pandemic: Results from Southern Italy.”, J Alzheimers Dis, vol. 76, no. 2, pp. 481-489, 2020.
, “Telomere Length and the Risk of Alzheimer's Disease: The Rotterdam Study.”, J Alzheimers Dis, vol. 73, no. 2, pp. 707-714, 2019.
, “Telomere Shortening in the Alzheimer's Disease Neuroimaging Initiative Cohort.”, J Alzheimers Dis, vol. 71, no. 1, pp. 33-43, 2019.
, “Temporal Order of Alzheimer's Disease-Related Cognitive Marker Changes in BLSA and WRAP Longitudinal Studies.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1335-1347, 2017.
, “Ten Challenges of the Amyloid Hypothesis of Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 447-457, 2017.
, “Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults.”, J Am Geriatr Soc, vol. 62, no. 1, pp. 16-24, 2014.
, “Testamentary Capacity Assessment Tool (TCAT): A Brief Instrument for Patients with Dementia.”, J Alzheimers Dis, vol. 61, no. 3, pp. 985-994, 2018.
, “Testing Hippocampal Memory in Prodromal Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 64, no. 2, pp. 349-353, 2018.
, “TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice.”, J Alzheimers Dis, vol. 56, no. 1, pp. 335-349, 2017.
, “A TgCRND8 Mouse Model of Alzheimer's Disease Exhibits Sexual Dimorphisms in Behavioral Indices of Cognitive Reserve.”, J Alzheimers Dis, vol. 51, no. 3, pp. 757-73, 2016.
, “Theobromine-Induced Changes in A1 Purinergic Receptor Gene Expression and Distribution in a Rat Brain Alzheimer's Disease Model.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1273-1283, 2017.
, “A Theoretical Analysis of the Synergy of Amyloid and Tau in Alzheimer's Disease.”, J Alzheimers Dis, vol. 52, no. 4, pp. 1461-70, 2016.
, “Therapeutics of Neurotransmitters in Alzheimer's Disease.”, J Alzheimers Dis, vol. 57, no. 4, pp. 1049-1069, 2017.
, “Is There a Characteristic Clinical Profile for Patients with Dementia and Sundown Syndrome?”, J Alzheimers Dis, vol. 62, no. 1, pp. 335-346, 2018.
,